Reading TARS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TARS free→Reading TARS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TARS free→QuarterlyIQ Insights · TARS
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 6, 2026, Tarsus Pharmaceuticals, Inc. (the “Company”) issued a press release, which, among other matters, sets forth the Company’s results of operations for the three months ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information, including Exhibit 99.1, is being furnished under
Results of Operations and Financial Condition. On February 23, 2026, Tarsus Pharmaceuticals, Inc. (the “Company”) issued a press release, which, among other matters, sets forth the Company’s results of operations for the year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information, including Exhibit 99.1, is being furnished under
Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers. On February 18, 2026, the Board of Directors (the “Board”) of Tarsus Pharmaceuticals, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee (the “Nominating Committee”), expanded the size of the Board from seven to eight directors and appointed David E.I. Pyott to the Board, effective immediately. Mr. Py…
Results of Operations and Financial Condition. On November 4, 2025, Tarsus Pharmaceuticals, Inc. (the “Company”) issued a press release, which, among other matters, sets forth the Company’s results of operations for the three and nine months ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information, including Exhibit 99.1, is being furnished under
Results of Operations and Financial Condition. On August 6, 2025, Tarsus Pharmaceuticals, Inc. (the “Company”) issued a press release, which, among other matters, sets forth the Company’s results of operations for the three and six months ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information, including Exhibit 99.1, is being furnished under
Results of Operations and Financial Condition. On May 1, 2025, Tarsus Pharmaceuticals, Inc. (the “Company”) issued a press release, which, among other matters, sets forth the Company’s results of operations for the three months ended March 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information, including Exhibit 99.1, is being furnished under
Entry into a Material Definitive Agreement. On March 12, 2025, Tarsus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into an Underwriting Agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, BofA Securities, Inc., and Barclays Capital Inc., acting as representatives of the underwriters named in the Underwriting Agreement (the “Underwriters”), relating to the sale of 2,808,988 shares of the Company’s common stock, par value $0.0001 per share (the “Offe…
Results of Operations and Financial Condition. On February 25, 2025, Tarsus Pharmaceuticals, Inc. (the “Company”) issued a press release, which, among other matters, sets forth the Company’s results of operations for the year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information, including Exhibit 99.1, is being furnished under
Departure of Directors or Certain Officers On January 15, 2025, Rosemary Crane, a member of the Board of Directors (the “Board”) of Tarsus Pharmaceuticals, Inc. (the “Company”) notified the Company of her resignation as a member of the Board and any committees of the Board, effective January 17, 2025. The resignation is not a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Effective January 17, 2025, the Company entered in…
Importance-ranked changes since the prior daily snapshot.
risk label changed from 'elevated' to 'moderate'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.